Dossier - 06/12/2019 Microbiome: human health is closely connected with our microbial communities People have 1.3 times more microorganisms than body cells. This microbial community influences how we digest our food, how active our immune system is, as well as whether we tend to be more anxious or curious. A number of diseases have also been shown to be associated with a disturbed microbiome. Researchers still have a long way to go before the knowledge acquired can be used for developing therapies.https://www.gesundheitsindustrie-bw.de/en/article/dossier/microbiome-human-health-closely-connected-with-microbial-communities
Article - 08/11/2019 Nanorobots as future minimally invasive tools for the eye It is difficult to place drugs in the right place in the eye. When using droplets, only a small fraction of the drug reaches its target. Injecting drugs into the eye is also more a matter of luck than judgement. Basic researchers at the Max Planck Institute for Intelligent Systems Stuttgart have developed a nanorobot that can be loaded with active ingredients for treating eye diseases and directed through the solid tissue of the vitreous body.https://www.gesundheitsindustrie-bw.de/en/article/news/Nanorobots-future-minimally-invasive-tools-for-eye
Article - 22/10/2019 Using CAR T cells for treating cancer After successes in the treatment of advanced blood cancers, CAR T-cell immunotherapy has become a major beacon of hope in oncology. The first therapies have received regulatory approval. Despite their success, these immunotherapies can have serious side effects. The company AVA Lifescience develops antibodies with high tumour specificity to use as the basis for effective precision-guided CAR T-cell therapies that are better tolerated by patients.https://www.gesundheitsindustrie-bw.de/en/article/news/using-car-t-cells-for-treating-cancer
Article - 01/07/2019 Microswimmers for guided drug delivery Medicines should act as quickly as possible and ideally only at the site of disease. However, this may be difficult when the medicines are taken up via the digestive tract or the blood system. Researchers at the Max Planck Institute for Intelligent Systems in Stuttgart have now developed a biohybrid microrobot consisting of red blood cells and bacteria that can be loaded with active ingredients.https://www.gesundheitsindustrie-bw.de/en/article/news/microswimmers-guided-drug-delivery
New edition - 24/05/2019 Tumour metastasis Cancer is usually not curable when metastases have formed in the body. Metastases are often resistant to drugs that have successfully eliminated the primary tumour. The basic features of the complex process of metastasis are now known, but many details still remain elusive. Intensive research activities are focusing on new therapeutic concepts aimed at developing effective anti-metastatic therapies.https://www.gesundheitsindustrie-bw.de/en/article/dossier/tumour-metastasis
Expert interview - 13/05/2019 Innovation management in the life sciences – Inova DE provides insights Personalized medicine, medical technology, digital health and artificial intelligence are revolutionizing diagnostics and product development. Analyses are becoming faster and more precise, and data volumes can now be networked and used effectively. The goal of improving people's quality of life is within reach, and this will also strengthen Germany’s future viability. However, not every good idea can be turned into a marketable commodity.…https://www.gesundheitsindustrie-bw.de/en/article/news/innovation-management-in-the-life-sciences-inova-de-provides-insights
Article - 16/04/2019 Tumour monitoring using liquid biopsy Liquid biopsy, the analysis of cancer biomarkers and circulating tumour cells in body fluids such as blood, is revolutionising the diagnosis and monitoring of cancer. It has also been possible to expand circulating tumour cells from the blood under laboratory conditions. It is expected that in the future, liquid biopsy will be able to precisely characterise tumour cells at every stage of a cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/tumour-monitoring-using-liquid-biopsy
Article - 28/03/2019 Supporting the human use of artificial intelligence Artificial intelligence is no longer a vision of the future, but is already in our midst: whether it is parking aids or search engines, we use the technology quite naturally in many areas of daily life. It promises new, unlimited opportunities, but also poses risks. Experts from the Integrata Foundation in Tübingen work on ethical issues and the human use of IT for improving the life of as many people as possible. https://www.gesundheitsindustrie-bw.de/en/article/news/supporting-the-human-use-of-artificial-intelligence
Article - 22/03/2019 Personalised therapies for treating metastasing breast cancer Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
Article - 07/02/2019 Artificial intelligence in ophthalmology Retinal diseases such as age-related macular degeneration (AMD) are now treatable. However, it is hard to predict individual disease progression. A group of researchers at the University Eye Centre in Freiburg are currently developing a new system which is hoped will allay fears and improve therapy planning. The system uses artificial intelligence to predict therapeutic outcome from image and patient data. Initial results are already available.https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-intelligence-in-ophthalmology
Article - 29/01/2019 Targeted RNA editing with the body’s own enzyme activity Completely new possibilities for research and gene therapy became available following the development of the CRISPR/Cas method for targeted modification of the genome. However, treatment with molecular scissors is not without risk as potential errors are stored in the genome forever. Scientists from Tübingen have developed an alternative method in which the intervention takes place at the RNA level using the body's own enzymes and is thus…https://www.gesundheitsindustrie-bw.de/en/article/news/targeted-rna-editing-with-the-bodys-own-enzyme-activity
Article - 10/01/2019 Stocktaking and recommendations for action: the BBAW’s fourth gene technology report In the new gene technology report, the interdisciplinary working group of the Berlin-Brandenburg Academy of Sciences (BBAW) takes stock of gene technology developments in Germany during the past few decades, and discusses the societal, legal and ethical challenges associated with these technologies in the future. The report is highly topical due to the controversy surrounding the ruling of the European Court of Justice on CRISPR/Cas9 genome…https://www.gesundheitsindustrie-bw.de/en/article/news/stocktaking-and-recommendations-for-action-the-bbaws-fourth-gene-technology-report
Dossier - 28/08/2018 With molecular diagnostics to biomarker-based personalised therapy Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.https://www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
Dossier - 06/03/2018 Big data - the big promise of the new digitised world https://www.gesundheitsindustrie-bw.de/en/article/dossier/big-data-the-big-promise-of-the-new-digitised-world
Dossier - 17/01/2017 Phytopharmaceuticals – fighting disease with natural substances https://www.gesundheitsindustrie-bw.de/en/article/dossier/phytopharmaceuticals-fighting-disease-with-natural-substances
Dossier - 14/06/2016 CRISPR/Cas – genome editing is becoming increasingly popular https://www.gesundheitsindustrie-bw.de/en/article/dossier/crisprcas-genome-editing-is-becoming-increasingly-popular
The Baden-Württemberg healthcare industry The pharmaceutical industry https://www.gesundheitsindustrie-bw.de/en/location/pharma
Dossier - 09/03/2015 Advances in the study and treatment of liver diseases https://www.gesundheitsindustrie-bw.de/en/article/dossier/advances-in-the-study-and-treatment-of-liver-diseases
Dossier - 10/11/2014 Cell and gene therapies from bench to bedside https://www.gesundheitsindustrie-bw.de/en/article/dossier/cell-and-gene-therapies-from-bench-to-bedside
Dossier - 30/06/2014 Addiction new concepts for resolving old problems https://www.gesundheitsindustrie-bw.de/en/article/dossier/addiction-new-concepts-for-resolving-old-problems
Dossier - 10/03/2014 Cancer therapy and cancer diagnostics https://www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-therapy-and-cancer-diagnostics
Dossier - 10/02/2014 Multiresistant pathogens a self-inflicted threat? https://www.gesundheitsindustrie-bw.de/en/article/dossier/multiresistant-pathogens-a-self-inflicted-threat
Dossier - 15/10/2013 Adult stem cells hope for regenerative therapies Adult stem cells have the lifelong ability to generate new specialised cells. They secure the continuous replenishment of cells therefore enabling the constant replacement of dying cells with new ones. Progress in the characterisation isolation and specific differentiation of adult stem cells over recent years raises hopes for the future use of the cells in the therapy of degenerative diseases. Knowledge about adult stem cells also has the…https://www.gesundheitsindustrie-bw.de/en/article/dossier/adult-stem-cells-hope-for-regenerative-therapies
Dossier - 21/05/2013 No new drugs to be placed on the market without clinical trials New pharmaceuticals are subject to approval by drug authorities. Prior to approval of a new pharmaceutical several hurdles such as preclinical and clinical studies need to be cleared. Clinical trials are performed to ensure the quality efficacy and safety of a medicinal product. Clinical development is a time-consuming and costly process and takes on average ten to fifteen years before a pharmaceutical company can apply for the approval of the…https://www.gesundheitsindustrie-bw.de/en/article/dossier/no-new-drugs-to-be-placed-on-the-market-without-clinical-trials